Write-ups of presentations on the 340B Drug Pricing Program were among the most viewed conference-related articles on the MHE website in 2025.

The most-viewed articles from our print publication included our November 2025 cover story on AI and our April 2025 cover story on Medicaid cuts.

Lytenava, an ophthalmic bevacizumab formulation to treat patients with wet age-related macular degeneration, received yet another FDA complete response letter. The agency is asking for confirmatory efficacy data beyond existing NORSE trial results.

Lucille Accetta, RPh, M.P.H., MBA, of CVS Health, foresees more progress in the push for simplification. A.J. Loiacono of Judi Health and Capital Rx, predicts unified management of healthcare financing and benefits on one "healthcare operating system."

Predictions from Tracy Baroni Allmon, BS Pharm, Eva Borden, Sharon Faust, Mike Kolodij, and James Margiotta

The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients experiencing increased skin cancer risk, highlighting the need for vigilant monitoring and innovative treatment strategies.

Predictions from Marci Chodroff, M.D., Jeffrey Casberg, RPh, M.S., Sarah Emond, M.P.P., Adam Kautzner, Pharm.D., David Fields, Nate Karnitz, MBA, and David Blair

New studies from the year revealed connections between medications, environmental factors and innovative treatments for skin conditions including vitiligo and atopic dermatitis.